Related Experiment Videos
Heating lyophilised factor VIII does not alter its recognition by specific antibodies
J G Gilles1, M di Giambattista, R Laub
1Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Belgium.
Vox Sanguinis
|January 1, 1997
Summary
Heat treatment of freeze-dried factor VIII (FVIII) preparations does not alter antibody reactivity, indicating resistance to denaturation. This finding is crucial for ensuring the safety and efficacy of FVIII therapies.
Area of Science:
- Biochemistry
- Immunology
- Hematology
Background:
- Factor VIII (FVIII) alterations during preparation can impact immunogenicity.
- Assessing FVIII reactivity with antibodies is a key evaluation method.
- Heat treatment is employed to mitigate viral transmission risks in FVIII products.
Purpose of the Study:
- To evaluate the immunoreactivity of plasma-derived FVIII after heat treatment.
- To determine the effects of varying temperatures and durations on FVIII structure and antibody binding.
- To validate a novel FVIII preparation's stability under thermal stress.
Main Methods:
- Plasma-derived FVIII was subjected to heat treatment at different temperatures (e.g., 80°C, 100°C) and durations.
- Immunoreactivity was assessed using specific rabbit antibodies and mouse monoclonal antibodies.
- FVIII activity was measured to quantify any functional loss post-heating.
Main Results:
- Heating FVIII up to 72 hours at 80°C did not affect its reactivity with polyclonal or monoclonal antibodies.
- Extended heating (72 hours at 80°C) resulted in some loss of FVIII activity.
- Heating at 100°C for 2 hours, causing ~50% activity loss, showed no significant impact on monoclonal antibody reactivity.
Conclusions:
- Freeze-dried plasma-derived FVIII preparations exhibit resistance to heat-induced structural denaturation.
- The findings support the stability of FVIII under thermal processing conditions.
- This suggests that heat treatment, as part of FVIII preparation, may not compromise its antigenic properties.